Neuroendocrine tumors: Insights into innovative therapeutic options and rational development of targeted therapies

Drug Discovery Today

Volumn 19, Issue 4, 2014, Pages 458-468

  Barbieri, Federica ^a   Albertelli, Manuela ^a   Grillo, Federica ^b   Mohamed, Amira ^c   Saveanu, Alexandru ^c,d   Barlier, Anne ^c,d   Ferone, Diego ^a   Florio, Tullio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c University of Mediterranée   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CIXUTUMUMAB; EVEROLIMUS; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PHARMACOLOGICAL BIOMARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CARCINOID; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG CHOICE; DRUG RESPONSE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPERPLASIA; MIXED TUMOR; MOLECULARLY TARGETED THERAPY; MUCOCARCINOID; NEUROENDOCRINE TUMOR; NOMENCLATURE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECANCER; PREDICTIVE VALUE; PSEUDOTUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION; ANIMAL; METABOLISM; NEUROENDOCRINE TUMORS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION;

EID: 84899535126     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.10.015     Document Type: Review

References (117)

1. B.I. Gustafsson et al. Neuroendocrine tumors of the diffuse neuroendocrine system Curr. Opin. Oncol. 20 2008 1 12
2. I.M. Modlin et al. Gastroenteropancreatic neuroendocrine tumours Lancet Oncol. 9 2008 61 72
3. I.M. Modlin et al. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant Langenbecks Arch. Surg. 396 2011 1145 1156
4. J.C. Yao et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J. Clin. Oncol. 26 2008 3063 3072
5. I.M. Modlin et al. Pharmacotherapy of neuroendocrine cancers Expert Opin. Pharmacother. 9 2008 2617 2626
6. S. McDermott et al. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach Clin. Imaging 37 2013 194 200
7. C. Toumpanakis, and M.E. Caplin Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors Semin. Oncol. 40 2013 56 68
8. D.S. Klimstra et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 2010 707 712
9. F. Bosman et al. WHO Classification of Tumors of the Digestive System 2010 WHO Press/IARC Press Lyon
10. G. Rindi et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Arch. 451 2007 757 762
11. G. Rindi et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Arch. 449 2006 395 401
12. M. Volante et al. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers Virchows Arch. 458 2011 393 402
13. G. Canavese et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior Hum. Pathol. 32 2001 1094 1101
14. U. Plockinger, and B. Wiedenmann Treatment of gastroenteropancreatic neuroendocrine tumors Virchows Arch. 451 Suppl. 1 2007 71 80
15. E. Bajetta et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 59 2007 637 642
16. S. Ekeblad et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin. Cancer Res. 13 2007 2986 2991
17. J.R. Strosberg et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
18. W.W. de Herder et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours Endocr. Relat. Cancer 10 2003 451 458
19. T. Florio Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors Front. Biosci. 13 2008 822 840
20. F. Barbieri et al. Peptide receptor targeting in cancer: the somatostatin paradigm Int. J. Pept. 2013 2013 926295
21. T. Florio Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases Mol. Cell. Endocrinol. 286 2008 40 48
22. F. Barbieri et al. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2 Endocrinology 149 2008 4736 4746
23. A. Massa et al. The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation J. Biol. Chem. 279 2004 29004 29012
24. T. Florio et al. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation Mol. Endocrinol. 15 2001 1838 1852
25. M.G. Pan et al. G protein activation of a hormone-stimulated phosphatase in human tumor cells Science 256 1992 1215 1217
26. M. Ruscica et al. Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression Curr. Mol. Med. 13 2013 555 571
27. S. Arena et al. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways Mol. Endocrinol. 19 2005 255 267
28. T. Florio et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities Endocrinology 144 2003 1574 1584
29. W. Bauer et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci. 31 1982 1133 1140
30. L. Canobbio et al. Use of long-acting somatostatin analog, lanreotide, in neuroendocrine tumors Oncol. Rep. 1 1994 129 131
31. C. Bruns et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur. J. Endocrinol. 146 2002 707 716
32. K. Oberg Established clinical use of octreotide and lanreotide in oncology Chemotherapy 47 Suppl. 2 2001 40 53
33. D. Ferone et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology J. Mol. Endocrinol. 42 2009 361 370
34. A. Schonbrunn Selective agonism in somatostatin receptor signaling and regulation Mol. Cell Endocrinol. 286 2008 35 39
35. F. Gatto, and L.J. Hofland The role of somatostatin and dopamine D2 receptors in endocrine tumors Endocr. Relat. Cancer 18 2011 R233 R251
36. G. Tulipano, and S. Schulz Novel insights in somatostatin receptor physiology Eur. J. Endocrinol. 156 Suppl. 1 2007 3 11
37. A. Rinke et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J. Clin. Oncol. 27 2009 4656 4663
38. O.H. Clark et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors J. Natl. Compr. Canc. Netw. 7 2009 712 747
39. L.K. Kvols et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study Endocr. Relat. Cancer 19 2012 657 666
40. A. Mohamed et al. First in vitro study of human gastroenteropancreatic- neuroendocrine tumors: comparative effect of octreotide and pasireotide Endocr. Abstr. 29 2012 OC9.6
41. K.Y. Gulenchyn et al. Radionuclide therapy in neuroendocrine tumours: a systematic review Clin. Oncol. 24 2012 294 308
42. S. Faiss et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J. Clin. Oncol. 21 2003 2689 2696
43. L.C. Platanias Introduction: interferon signals: what is classical and what is nonclassical? J. Interferon Cytokine Res. 25 2005 732
44. L. Dahan et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr. Relat. Cancer 16 2009 1351 1361
45. J.A. Gilbert et al. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors Endocr. Relat. Cancer 17 2010 623 636
46. A. Couvelard et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression Br. J. Cancer 92 2005 94 101
47. J.Y. Scoazec Angiogenesis in neuroendocrine tumors: therapeutic applications Neuroendocrinology 97 2013 45 56
48. M.H. Kulke et al. Activity of sunitinib in patients with advanced neuroendocrine tumors J. Clin. Oncol. 26 2008 3403 3410
49. E. Raymond et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 501 513
50. S. Faivre et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib Target. Oncol. 7 2012 127 133
51. A.T. Phan et al. A prospective, multi-institutional Phase II study of GW786034 (pazopanib) and depot octreotide (Sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) J. Clin. Oncol. 28 Suppl. 2010 301
52. T. Delaunoit et al. Medical management of pancreatic neuroendocrine tumors Am. J. Gastroenterol. 103 2008 475 484
53. A. Polverino et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res. 66 2006 8715 8721
54. J.C. Yao et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment Phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J. Clin. Oncol. 26 2008 1316 1323
55. A. Koumarianou et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Endocr. Relat. Cancer 19 2012 L1 L4
56. M.H. Kulke et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J. Clin. Oncol. 24 2006 401 406
57. M. Furukawa et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases Clin. Cancer Res. 11 2005 3233 3242
58. M. Hopfner et al. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours Endocr. Relat. Cancer 13 2006 135 149
59. D.L. Reidy et al. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors Nat. Clin. Pract. Oncol. 6 2009 143 152
60. H. Zhou, and S. Huang Role of mTOR signaling in tumor cell motility, invasion and metastasis Curr. Protein Pept. Sci. 12 2011 30 42
61. R. Zoncu et al. mTOR: from growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 12 2011 21 35
62. R. Goldstein, and T. Meyer Role of everolimus in pancreatic neuroendocrine tumors Expert Rev. Anticancer Ther. 11 2011 1653 1665
63. D.D. Sarbassov et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
64. J. Heitman et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 1991 905 909
65. D. Benjamin et al. Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discov. 10 2011 868 880
66. E. Jacinto et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat. Cell Biol. 6 2004 1122 1128
67. K. Maiese et al. mTOR: on target for novel therapeutic strategies in the nervous system Trends Mol. Med. 19 2013 51 60
68. Y. Jiao et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
69. E. Missiaglia et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J. Clin. Oncol. 28 2010 245 255
70. I. Duran et al. A Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br. J. Cancer 95 2006 1148 1154
71. P.J. Houghton Everolimus Clin. Cancer Res. 16 2010 1368 1372
72. J.C. Yao et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial J. Clin. Oncol. 28 2010 69 76
73. M.E. Pavel et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study Lancet 378 2011 2005 2012
74. J.C. Yao et al. Everolimus for advanced pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 514 523
75. J.C. Yao et al. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience Cancer Res. 73 2013 1449 1453
76. J.A. Chan et al. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors Cancer Chemother. Pharmacol. 71 2013 1241 1246
77. F. Meric-Bernstam et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors Clin. Cancer Res. 18 2012 1777 1789
78. L. Bodei et al. Peptide receptor therapies in neuroendocrine tumors J. Endocrinol. Invest. 32 2009 360 369
79. K. Oberg et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 23 Suppl. 7 2012 124 130
80. M. Pavel et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157 176
81. K. Oberg et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy Neuroendocrinology 90 2009 209 213
82. D. Ferone Somatostatin and dopamine receptors Tumori 96 2010 802 805
83. P. Ameri, and D. Ferone Diffuse endocrine system, neuroendocrine tumors and immunity: what's new? Neuroendocrinology 95 2012 267 276
84. I.M. Modlin et al. Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease Ann. Surg. Oncol. 17 2010 2427 2443
85. M.S. Khan et al. Circulating tumor cells and EpCAM expression in neuroendocrine tumors Clin. Cancer Res. 17 2011 337 345
86. I.M. Modlin et al. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood PLoS One 8 2013 e63364
87. S.C. Li et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors Mod. Pathol. 26 2013 685 696
88. M.H. Kulke et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin. Cancer Res. 15 2009 338 345
89. T. Gagliano et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids Endocr. Relat. Cancer 20 2013 463 475
90. T. Florio, and F. Barbieri The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells Drug Discov. Today 17 2012 1103 1110
91. K. Shien et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells Cancer Res. 73 2013 3051 3061
92. P. Gaur et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors Gastroenterology 141 2011 1728 1737
93. T.R. Wilson et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
94. K. Oberg et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches Clin. Cancer Res. 19 2013 2842 2849
95. L.H. Tang et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6 Clin. Cancer Res. 18 2012 4612 4620
96. R. Dammann et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis Histol. Histopathol. 18 2003 665 677
97. A. Karpathakis et al. Neuroendocrine tumours: cracking the epigenetic code Endocr. Relat. Cancer 20 2013 R65 R82
98. J.C. Reubi et al. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications J. Steroid Biochem. Mol. Biol. 43 1992 27 35
99. F. Gatto et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly J. Clin. Endocrinol. Metab. 98 2013 E66 E71
100. F. Gatto et al. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins Clin. Endocrinol. 76 2012 407 414
101. G.F. Taboada et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR Eur. J. Endocrinol. 158 2008 295 303
102. G.F. Taboada et al. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas Neuroendocrinology 93 2011 40 47
103. M. Theodoropoulou et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression Cancer Res. 66 2006 1576 1582
104. M. Duran-Prado et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors J. Clin. Endocrinol. Metab. 94 2009 2634 2643
105. M. Duran-Prado et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs J. Clin. Endocrinol. Metab. 95 2010 2497 2502
106. R.K. Jain et al. Biomarkers of response and resistance to antiangiogenic therapy Nat. Rev. Clin. Oncol. 6 2009 327 338
107. S. Loges et al. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates Genes Cancer 1 2010 12 25
108. K.M. Detjen et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors Clin. Cancer Res. 16 2010 420 429
109. Y. Arvidsson et al. Hypoxia stimulates CXCR4 signalling in ileal carcinoids Endocr. Relat. Cancer 17 2010 303 316
110. W. Rostene et al. Chemokines and chemokine receptors: new actors in neuroendocrine regulations Front. Neuroendocrinol. 32 2011 10 24
111. X.H. Yao et al. Contribution of cancer stem cells to tumor vasculogenic mimicry Protein Cell 2 2011 266 272
112. M. Paez-Ribes et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
113. B. Sennino, and D.M. McDonald Controlling escape from angiogenesis inhibitors Nat. Rev. Cancer 12 2012 699 709
114. M. Breuleux et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol. Cancer Ther. 8 2009 742 753
115. X. Wan et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940
116. R. Quek et al. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors Clin. Cancer Res. 17 2011 871 879
117. J. Strosberg et al. A multi-institutional, Phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors Endocr. Relat. Cancer 20 2013 383 390